Biocon’s moment of reckoning

With biosimilars in the limelight, Kiran Mazumdar-Shaw’s company is poised to become one of India’s most important drug makers

21 April, 202012 min
0
Biocon’s moment of reckoning

You may also like

Internet
Story image

Takeaways from Dubizzle’s rare pause on IPO

The classifieds company postponed its influential public listing on the Dubai stock exchange. A mismatch of expectations was at the core of it.

Business
Story image

Can Meesho’s value-commerce playbook pass the IPO test?

The ecommerce platform will be hard-pressed to justify its estimated $7-8 billion valuation—up nearly 2x from just 10 months ago—at a time of ho-hum growth and flagging profitability.

Internet
Story image

A guide to understanding Dubizzle’s high-profile public listing

The popular classifieds company has just announced a public offering in Dubai and filed its prospectus. We take a look at its trajectory and timing.